Diabetes Clinical Trials in Las Vegas
View 48 new treatments for Diabetes in Las Vegas, NV, and nearby areas, such as Henderson. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Las Vegas + 2 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 3 - 6 Weeks
Glenn Crater, MD
Study Director
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Eli Lilly Clinic, Las Vegas + 2 more
This trial is testing a new medication called tirzepatide for people with type 2 diabetes. Tirzepatide helps control blood sugar by making the body produce more insulin and reducing appetite. The study aims to see if switching to this new treatment is more effective than current therapies.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Faricimab for Diabetic Macular Edema
Genentech Clinic, Las Vegas + 1 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Clinical Trials
Study Director
Naltrexone + Bupropion for Obesity
Currax Clinic, Las Vegas + 2 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Mifepristone for Type 2 Diabetes
Corcept Clinic, Las Vegas + 1 more
This trial is testing mifepristone, a medication that blocks cortisol, in patients with hard-to-control type 2 diabetes and high cortisol levels. The goal is to see if mifepristone can help manage their blood sugar better than standard treatments alone. Mifepristone has been studied for various conditions including Cushing's syndrome, psychotic depression, and cognitive decline in Alzheimer's disease.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Daniel Einhorn, MD
Study Director
Retatrutide vs Semaglutide for Type 2 Diabetes
Eli Lilly Clinic, Las Vegas + 2 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Orforglipron for Obesity
Eli Lilly Clinic, Las Vegas + 1 more
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Semaglutide for Diabetic Eye Disease
Novo Nordisk Clinic, Las Vegas + 2 more
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Clinical Reporting Anchor and Disclosure (1452)
Study Director
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Las Vegas + 1 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than just using one of the drugs alone. Participants will receive either IcoSema or the single drug and will be monitored for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
Novo Nordisk Clinic, Las Vegas + 1 more
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Page 1 of 5
Frequently Asked Questions
Explore related conditions